12:00 AM
 | 
Sep 16, 2013
 |  BioCentury  |  Strategy

Alzumab's (re)mission statement

How Biocon aims to take on anti-TNF-alpha mAbs by targeting CD6

Biocon Ltd. is betting the long remission time and reduced opportunistic infections associated with its Alzumab itolizumab will pull doctors away from biologics with better efficacy in psoriasis.

The company has long maintained that the first-in-class biologic has a safety advantage over competing psoriasis biologics. Now the long-term data it is collecting from its psoriasis trials are providing a new selling point for the drug - duration of remission.

It's still unclear whether those benefits will be enough to pull patients and doctors away from competitor drugs that have markedly better response rates. India will be the testing ground, as Biocon launched the anti-CD6 mAb there in August. The company hopes to use its sales performance to attract a partner for development and commercialization elsewhere.

In January, India approved Alzumab to treat chronic plaque psoriasis. The mAb blocks aberrant activation of CD6 on Th17 cells that leads to production of high levels of multiple proinflammatory cytokines that contribute...

Read the full 783 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >